|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett's esophagus.
|
24357184 |
2014 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
TLR4 activation in BE results in a strong increase in COX-2 and may contribute to malignant transformation.
|
23955118 |
2014 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To examine the expression of VEGF, COX-2 and Ki-67 in BE and investigate whether there is an association to Barrett's length.
|
22147251 |
2012 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Wnt and cyclooxygenase 2 (Cox2) are two pathways whose activation has been associated with BE and progression to EAC, but their role has not been tested experimentally.
|
21969813 |
2011 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
FASN is strongly expressed in the intestinal mucin phenotype of Barrett's esophagus, in which Barrett's glandular cells display elevated cellular proliferation, angiogenesis, and COX-2 expression.
|
21325951 |
2011 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
COX-2 and, especially, EP2 were increased in the Barrett's metaplasia-intraepithelial neoplasia-adenocarcinoma sequence.
|
19843025 |
2010 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
First, expression of HPSE and COX-2 in 78 clinical tissues of Barrett's oesophagus was examined by immunohistochemistry and in situ hybridization.
|
20653782 |
2010 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the expression of COX-2 in rat model of BE and examined the usefulness of COX-2 expression in determining the risk of malignant transformation in patients with BE treated with argon plasma coagulation (APC) that allows for effective ablation of metaplastic mucosa (group A) without or with proton pump inhibitors (PPI).
|
20814068 |
2010 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
RGD |
[Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide].
|
17675820 |
2007 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increasing COX-2 expression in Barrett's metaplasia is significantly associated with a change in the local inflammatory reaction, but not during further progression through dysplasia to cancer.
|
17222248 |
2007 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
COX-2 and EGFR may be cooperative in the stepwise progression from BE to EAC, thereby leading to carcinogenesis.
|
16521222 |
2006 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The presence of esophagitis or Barrett's esophagus did not significantly alter the expression of Cox-2 compared to patients with nonerosive reflux disease (NERD).
|
16863546 |
2006 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
|
16550596 |
2006 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
LHGDN |
COX-2 and EGFR may be cooperative in the stepwise progression from BE to EAC, thereby leading to carcinogenesis.
|
16521222 |
2006 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
|
17244951 |
2006 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
COX-2 and prostaglandin E(2) expression were evaluated by Western blotting and enzyme-linked immune assay in samples of squamous esophagus, Barrett's esophagus with varying degrees of dysplasia to adenocarcinoma, and normal duodenum.
|
15269153 |
2004 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Acid exposure has been shown both to activate the MAPK pathways and to increase COX-2 protein expression in Barrett's metaplasia, but it is not known whether these effects are interrelated.
|
15231484 |
2004 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
|
15387324 |
2004 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The occurrence of substantial alterations in Cox-1 and Cox-2 expression at the BE stage indicates that these are early events in the development of EAC.
|
15585388 |
2004 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that acid-induced activation of the MAPK pathways mediates an increase in COX-2 expression in Barrett's esophagus, and we tested this hypothesis in a Barrett's-associated adenocarcinoma cell line (SEG-1).
|
15231484 |
2004 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased COX-2 expression did not differ during the progression from Barrett's oesophagus negative for dysplasia to Barrett's adenocarcinoma and is related to adenocarcinoma whose histology is well differentiated.
|
12713622 |
2003 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The COX-2 enzyme has been reported to be over-expressed in premalignant and malignant states, including in Barrett's esophagus and esophageal adenocarcinoma.
|
14641306 |
2003 |
|
Barrett Esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
|
11059772 |
2000 |
|
Barrett Esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase (COX)-2 appears to play an important role in gastrointestinal carcinogenesis, and COX-2 overexpression has been demonstrated both in esophageal adenocarcinomas and in the metaplastic epithelium of Barrett's esophagus.
|
11059772 |
2000 |